Canadians are being urged to stop using a common pain relief medication after Health Canada issued a recall due to potential contamination.
The recall affects Novo-Gesic Forte 500 mg acetaminophen tablets distributed by Teva Canada Limited, a Toronto-based pharmaceutical company. Health Canada announced the recall on Tuesday, citing concerns about possible contamination with phenolic resin or epoxy substances.
Potential Health Risks Identified
If consumed, these contaminants could cause serious injury to the digestive system, according to regulatory officials. The affected medication was originally supplied to pharmacies in large 1,000-count bottles, though it was typically dispensed to patients in smaller quantities.
Health Canada emphasized that the recall covers one specific lot of the medication. The agency is actively monitoring the situation and overseeing Teva Canada’s corrective measures. “Health Canada is monitoring the recall and the company’s preventative and corrective actions,” the statement read. “If additional safety concerns arise, Health Canada will take appropriate action and inform Canadians as needed.”
Immediate Actions for Consumers
Canadian consumers currently using the affected product are advised to discontinue use immediately. Health Canada recommends returning any remaining medication to the pharmacy where it was originally purchased for proper replacement and disposal.
“Individuals who have used the affected product and have health concerns should consult their healthcare provider,” Health Canada advised. This guidance underscores the importance of professional medical consultation for anyone experiencing unusual symptoms after taking the medication.
Contact Information and Reporting
Patients and healthcare providers can reach Teva Canada’s Customer Care service for assistance with the recall process. Additionally, Canadians are encouraged to report any adverse reactions or side effects related to the medication directly to Health Canada’s adverse reaction reporting system.
The recall demonstrates Health Canada’s ongoing commitment to pharmaceutical safety monitoring and rapid response to potential health threats. Regulatory officials continue investigating how the contamination occurred and what preventive measures can be implemented to avoid similar incidents in the future.
Why it Matters
This recall highlights the critical importance of robust pharmaceutical quality control systems and transparent communication between regulators and the public. Acetaminophen is one of the most widely used over-the-counter medications in Canada, making its safety a matter of public health significance. The incident serves as a reminder that even routine medications carry potential risks when manufacturing standards are compromised, underscoring the vital role of vigilant regulatory oversight in protecting consumer health and maintaining confidence in the healthcare system.
